Novartis AG
Novartis AG (NVSEF) Revenue
Annual & quarterly revenue history · segment & region breakdown
NVSEF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsNovartis AG trailing twelve-month (TTM) revenue is $55.50B, an increase of 10.45% year-over-year from $57.13B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $57.13B | +$5.40B | +10.45% |
| 2024-12-31 | $51.72B | +$5.06B | +10.85% |
| 2023-12-31 | $46.66B | -$5.17B | -9.97% |
| 2022-12-31 | $51.83B | -$1.05B | -1.98% |
| 2021-12-31 | $52.88B | +$2.98B | +5.97% |
| 2020-12-31 | $49.90B | +$1.22B | +2.51% |
| 2019-12-31 | $48.68B | -$4.49B | -8.44% |
| 2018-12-31 | $53.17B | +$3.03B | +6.05% |
| 2017-12-31 | $50.13B | +$0.70B | +1.41% |
| 2016-12-31 | $49.44B | -$0.95B | -1.89% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare NVSEF revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Novartis AG receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Novartis AG reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Novartis AG's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NVSEF revenue · 5 questionsNVSEF's trailing twelve-month (TTM) revenue is $55.50B. That is an increase of 10.45% year-over-year from $57.13B in FY2025.
▸ Source: FMP · Novartis AG SEC filings · GAAP · Novartis AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026